In contrast, PI3KCA mutations were detected in 34.5% of hormone receptor-positive cancers, 22.7% of 75 HER2-positive cancers, 8.3% of basal-like cancers and none of claudin-low tumors examined in this study. The gene discussed is ERBB2; the disease is cancer.